Xellia Pharmaceuticals


Dalslandsgade 11
2300 Copenhagen S


+45 3624 5500


Xellia Pharmaceuticals is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections. Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as finished dosage forms, where the majority are injectable drug products.

Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway, Denmark, Hungary and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers.

Our product portfolio of anti-bacterial and anti-fungal products used for the treatment of severe infections, including infections caused by multi-resistant bacteria and fungi, is the foundation for our growth strategy within the antibiotics’ sector.

Xellia is the leading supplier of important anti-infectives vancomycin and colistimethate sodium (CMS). Our success and strong market position is built on more than 115 years’ of pharmaceutical industry experience. Xellia Pharmaceuticals’ focus its R&D investments within inhalable and injectable product technologies as we are committed to researching solutions, which improve patients’ quality of life.

LinkedIn: https://www.linkedin.com/company/1181570

View the Corporate Report 2019 here.